Warby Parker
WRBY
$25.48
-2.30%
Warby Parker Inc. is a vertically integrated, mission-driven eyewear brand that designs, manufactures, and sells prescription glasses, sunglasses, contact lenses, and related accessories, while also delivering optical services and eye exams through a growing network of physical stores and its e-commerce and mobile platforms. The company operates as a direct-to-consumer disruptor in the traditionally intermediated optical retail market, using in-house design, owned-and-operated retail locations, and a home try-on model to undercut legacy players on price while positioning itself as a lifestyle brand at the intersection of design, technology, and healthcare. The current investor narrative centers on the company's transition from a high-growth, cash-burning DTC story into a profitable, store-driven omnichannel retailer, with attention focused on the pace of new store openings, the scaling of its contact lens and eye exam businesses, and the durability of gross margin gains as it pushes toward sustained GAAP profitability. Debate also hinges on whether the recent deceleration in revenue growth and a soft fourth quarter reflect temporary macro pressure on discretionary consumer spending or a more structural maturation of the core eyewear category, making the margin trajectory and store-level unit economics the key swing factors for the stock.…
WRBY
Warby Parker
$25.48
Related headlines
Investment Opinion: Should I buy WRBY Today?
Rating: Hold with a constructive bias. The core thesis is that Warby Parker has genuinely crossed the profitability inflection — Q2 2026 net income of $4.64 million versus a $1.75 million loss a year earlier, gross margin up roughly 500bps to 57.94%, and EBITDA nearly doubling to $19.32 million — but at $26.08 the stock already discounts much of that improvement, leaving only +18.9% upside to the $31.00 average analyst target against a beta of 1.952 and a 42.42x forward PE. The 10 Buy / 3 Hold / 0 Sell consensus (recommendation mean 1.62) supports owning the name, but the flat 1-month (-0.57%) and negative 6-month (-11.74%) price action argues for patience rather than chasing the +22.50% single-day spike.
The supporting evidence is real but narrow. Gross margin of 57.94% is well above the low-30s to low-40s typical of mass retail, operating income swung positive to $3.17 million (1.34% margin) from a $4.53 million loss, and free cash flow of $21.75 million TTM remains positive despite $22.86 million of quarterly capex. The balance sheet is a genuine asset — $292.67 million of cash and a 2.35 current ratio fund the store rollout without dilution, and debt-to-equity of 0.63 is manageable. Against that, revenue growth has decelerated to 9.81% YoY, Q4 2025 revenue fell sequentially to $211.97 million from $221.68 million, and the 3.07x PS and 49.13x EV/EBITDA multiples are only defensible if double-digit growth and margin expansion both continue.
The biggest risks that could invalidate the thesis are a gross margin slip back toward the 52.97% level of Q2 2025 (which would erase GAAP profit given a 0.19% trailing net margin), a further deceleration in the core eyewear business that is $191.76 million of $235.51 million in revenue, and multiple compression from 42.42x forward PE toward a mid-20s multiple if the $1.38 forward EPS estimate is cut. This Hold would upgrade to Buy on a decisive break above the $31.00 52-week high accompanied by gross margin holding above 57% and revenue growth reaccelerating above 12%, and would downgrade to Sell on a close below the $21.29 recent low or a forward EPS revision below $1.20. On balance the stock looks fairly valued to modestly undervalued relative to its own history — PS of 3.07x versus a historical band of roughly 7x to 39x — but expensive relative to brick-and-mortar retail peers, so the verdict is fair value with an upward tilt contingent on execution.
Sign up to view all
WRBY 12-Month Price Forecast
The forward view is balanced: the profitability inflection is genuine and margin-driven, but the 42.42x forward PE already prices in the $1.38 EPS estimate, and sub-10% revenue growth limits how much multiple expansion is available. The PS ratio of 3.07x sits near the low end of a historical 7x-to-39x band, which caps further de-rating risk, while the $292.67 million cash balance and positive $21.75 million TTM free cash flow fund the store rollout without dilution. Analyst sentiment is strongly positive but the flat-to-negative price action shows the market is waiting for confirmation rather than paying for the story. I would upgrade to bullish on a decisive break above $31.00 with gross margin holding above 57% and revenue growth reaccelerating above 12%, and downgrade to bearish on a close below $21.29 or a forward EPS revision below $1.20.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Warby Parker's 12-month outlook, with a consensus price target around $31.00 and implied upside of +21.7% versus the current price.
Average Target
$31.00
13 analysts
Implied Upside
+21.7%
vs. current price
Analyst Count
13
covering this stock
Price Range
$25 - $35
Analyst target range
Coverage is reasonably robust for a mid-cap retailer, with 12 analysts publishing ratings and a distribution of 10 Buy, 3 Hold, and 0 Sell, yielding a consensus recommendation of "buy" and a recommendation mean of 1.62 on a scale where 1 is a strong buy. The average target price of $31.00 implies roughly +18.9% upside from the current $26.08, and the consensus is clearly bullish, with more than 80% of covering analysts positive on the name. That said, the bullish consensus stands in tension with the stock's flat 1-month and negative 3-month and 6-month performance, suggesting analysts are looking through near-term weakness toward the forward EPS estimate of $1.38 and revenue estimate of $1.86 billion.
The target range of $25.00 to $35.00 is moderately wide, spanning about 40% from low to high, which signals meaningful dispersion in assumptions about the pace of margin expansion and store growth. The $35.00 high target likely assumes accelerating revenue growth, continued gross margin expansion above 58%, and multiple expansion as the company proves durable profitability, while the $25.00 low target sits essentially at the current price and implies skepticism about the earnings inflection or concern that consumer discretionary spending remains soft. Institutional ratings show a stable-to-cautiously-constructive pattern, with Citizens maintaining Market Outperform, BTIG reiterating Buy, and Telsey staying Outperform, while UBS, Citigroup, and Stifel remain Neutral or Hold; the absence of recent upgrades or downgrades suggests analysts are in a wait-and-see posture ahead of the next earnings print, and the tight clustering of targets near the average indicates moderate conviction rather than a high-conviction call.
Bulls vs Bears: WRBY Investment Factors
The bear case currently has slightly stronger near-term evidence: revenue growth has decelerated to 9.81%, the stock is down 11.74% over six months and lagging SPY by 11.11%, and the 42.42x forward PE prices in an earnings inflection that has only just begun to appear in the numbers. The bull case, however, is not weak — gross margin expansion of roughly 500bps, a swing to positive operating income, and a PS multiple near the bottom of its historical range suggest the de-rating is largely done and the profitability story is genuine. The single most important tension is whether the margin trajectory can carry the valuation: if gross margins hold near 58% and operating leverage continues, the 42x forward multiple is defensible on a company inflecting to mid-teens operating margins, but if growth stays below 10% and margins stall, the multiple compresses toward the $25 low target and below. Analyst consensus (10 Buy, 0 Sell, $31 average target) leans bullish, but the flat-to-negative price action shows the market is waiting for confirmation rather than paying for the story in advance.
Bullish
- Gross margin expanded ~500bps YoY: Q2 2026 gross margin reached 57.94% versus 52.97% in Q2 2025, a roughly 500-basis-point gain driven by product mix, pricing, and supply chain leverage. This is the clearest evidence of operating leverage in the model, and it is what makes the forward EPS estimate of $1.38 plausible against trailing EPS of essentially zero.
- Profitability inflection is real, not theoretical: Q2 2026 net income of $4.64 million marked a swing from a $1.75 million loss a year earlier, operating income turned positive at $3.17 million versus a $4.53 million loss, and EBITDA nearly doubled to $19.32 million from $9.95 million. Three of the last four quarters have now posted positive net income, so the inflection is a trend rather than a one-off.
- Analyst consensus strongly bullish with upside: Ten of twelve covering analysts rate WRBY a Buy with zero Sells, a recommendation mean of 1.62, and an average target of $31.00 implying +18.9% upside from $26.08. The $35.00 high target implies roughly +34% upside and reflects a credible path to margin expansion and multiple re-rating.
- Valuation de-rated far from peak multiples: The PS ratio of 3.07x sits near the low end of a historical band that ranged roughly 7x to 39x, versus 39.42x at the Q4 2021 peak. The market has already absorbed substantial multiple compression, so the downside from further de-rating is more limited than at any prior point in the company's public history.
Bearish
- Revenue growth decelerated to single digits: Q2 2026 revenue of $235.51 million grew just 9.81% YoY, down from the high-teens rates investors once expected, and Q4 2025 revenue of $211.97 million actually fell sequentially from Q3 2025's $221.68 million. A 42.42x forward PE is hard to defend on sub-10% top-line growth unless margins expand aggressively.
- Valuation rests entirely on an unproven inflection: The 42.42x forward PE against a 1,626x trailing PE means the entire valuation depends on EPS jumping from $0.0006 to $1.38. EV/EBITDA of 49.13x on a still-depressed ~$19 million quarterly EBITDA base leaves little room for execution error, and any margin slippage would compress the multiple sharply.
- Margins are razor-thin with no cushion: Trailing operating margin is -0.61% and net margin just 0.19%, while ROE of 0.45% and ROA of -1.02% confirm depressed returns on capital. With stock-based compensation of $9.90 million in the quarter, true economic profitability is weaker than GAAP net income suggests, and SG&A creep would erase the profit entirely.
- Momentum has broken down despite the 1-year gain: The 6-month change is -11.74% and relative strength versus SPY has flipped from +28.72% over 1 year to -11.11% over 6 months, with 1-month and 3-month changes of -0.57% and -1.44%. The stock has repeatedly failed at the $29-$31 resistance zone, and the recent +22.50% single-day spike leaves it extended and vulnerable to retracement.
WRBY Technical Analysis
WRBY is in a choppy, range-bound recovery phase rather than a clean uptrend, with a 1-year price change of +36.90% that masks substantial intra-year volatility. At the current price of $26.08, the stock sits roughly 84% of the way through its 52-week range of $14.96 to $31.00, positioning it in the upper portion of the band but still about 16% below the 52-week high. That location implies residual momentum from the powerful 1-year advance but also meaningful overhead supply, and the stock has repeatedly failed to hold above the $30-$31 resistance zone, suggesting the market is not yet willing to pay for a breakout to new highs.
Short-term momentum is weak and diverging from the longer-term trend: the 1-month change is -0.57% and the 3-month change is -1.44%, both flat-to-negative even as the 1-year figure remains strongly positive at +36.90%. The 6-month change of -11.74% confirms that the intermediate trend has been a slow bleed lower, and the stock's relative strength versus SPY has deteriorated from +28.72% over 1 year to -11.11% over 6 months, meaning WRBY has recently been a laggard despite its annual outperformance. The most recent session, however, delivered a violent +22.50% single-day move from $21.29 to $26.08 on elevated volume of roughly 11.26 million shares, a gap that likely reflects a major catalyst and has left the stock extended in the very short term, raising the risk of a partial retracement of that spike.
Key technical levels are well defined: support sits at the $21.29-$21.94 area established by the recent low, with deeper support at the 52-week low of $14.96, while resistance is anchored at the $31.00 52-week high and the $29-$30 zone where the stock repeatedly stalled in June and August. A decisive breakout above $31.00 would signal a new leg higher and validate the recovery, whereas a breakdown below $21.29 would reopen the path toward the mid-teens and suggest the recent gap was a failed spike. With a beta of 1.952, WRBY is nearly twice as volatile as the S&P 500, and a maximum drawdown of -39.22% over the period underscores that position sizing and stop discipline are critical; the elevated short ratio of 5.88 days-to-cover also implies squeeze potential that can amplify moves in either direction.
Beta
1.95
1.95x market volatility
Max Drawdown
-37.6%
Largest decline past year
52-Week Range
$16-$31
Price range past year
Annual Return
+50.5%
Cumulative gain past year
| Period | WRBY Return | S&P 500 |
|---|---|---|
| 1m | +0.7% | -5.4% |
| 3m | -3.7% | -4.9% |
| 6m | -13.8% | -0.3% |
| 1y | +50.5% | +9.7% |
| ytd | +12.6% | +7.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WRBY Fundamental Analysis
Revenue growth has decelerated to a more modest pace, with the most recent quarter (Q2 2026, ended June 30, 2026) posting revenue of $235.51 million, up 9.81% year-over-year from $214.48 million in Q2 2025. The multi-quarter trend shows sequential revenue of $242.45 million in Q1 2026, $211.97 million in Q4 2025, and $221.68 million in Q3 2025, indicating a business that is growing but no longer compounding at the high-teens rates investors once expected, and the Q4 2025 sequential dip highlights seasonality and holiday-quarter softness. Eyewear products remain the dominant revenue line at $191.76 million, meaning the growth story is still overwhelmingly dependent on the core glasses business rather than contacts or services, which limits diversification and makes the 9.81% YoY growth rate the key metric to watch for signs of reacceleration or further deceleration.
Profitability has improved meaningfully but remains thin: Q2 2026 net income was $4.64 million (a 1.97% net margin) versus a net loss of $1.75 million in Q2 2025, and gross margin expanded to 57.94% from 52.97% a year earlier, a roughly 500-basis-point improvement that reflects better product mix, pricing, and supply chain leverage. Operating income turned positive at $3.17 million (1.34% operating margin) compared with an operating loss of $4.53 million in the prior-year quarter, and EBITDA rose to $19.32 million from $9.95 million, showing real operating leverage. Still, the trailing operating margin of -0.61% and net margin of just 0.19% underscore that the company is only marginally profitable and highly sensitive to any gross margin slippage or SG&A creep, leaving little cushion if growth slows further.
Balance sheet and cash flow metrics are solid but not fortress-like: the current ratio of 2.35 and cash balance of $292.67 million provide ample near-term liquidity, while debt-to-equity of 0.63 is manageable for a retailer with substantial lease obligations. Free cash flow is positive but modest at $21.75 million TTM, and Q2 2026 free cash flow of $6.76 million was constrained by $22.86 million of capital expenditures, reflecting the capital intensity of store expansion; operating cash flow of $29.62 million covered capex only about 1.3x. ROE of just 0.45% and ROA of -1.02% confirm that returns on capital remain depressed, and with stock-based compensation of $9.90 million in the quarter, the company still relies on equity compensation to preserve cash, meaning true economic profitability is weaker than GAAP net income suggests.
Quarterly Revenue
$244735000.0B
2026-09
Revenue YoY Growth
+10.4%
YoY Comparison
Gross Margin
54.4%
Latest Quarter
Free Cash Flow
$21286999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WRBY Overvalued?
Because trailing net income is barely positive, the trailing PE of 1,626x is economically meaningless and I have selected the forward PE and price-to-sales ratio as the primary metrics. The forward PE of 42.42x against a trailing PE of 1,626x implies the market expects earnings to inflect dramatically, consistent with consensus EPS estimates of $1.38 for the forward period versus the current $0.0006 trailing EPS; the PS ratio of 3.07x and EV/sales of 2.84x are more grounded measures of what investors are paying for the revenue base. The enormous gap between trailing and forward earnings multiples signals that the entire valuation rests on the profitability inflection materializing, leaving little room for execution error.
Relative to the specialty retail sector, WRBY's 3.07x PS and 2.84x EV/sales represent a premium to typical brick-and-mortar optical and apparel retailers, which often trade at 1x-2x sales, though the company's 53.97% gross margin is well above the low-30s to low-40s typical of mass retail. The 49.13x EV/EBITDA multiple is rich for a retailer and reflects the still-depressed EBITDA base of roughly $19 million per quarter rather than a durable earnings stream, while the 7.27x price-to-book and 24.13x price-to-cash-flow ratios sit at the high end of retail comparables. The premium is defensible only if the company sustains double-digit revenue growth and continues expanding margins toward the mid-teens operating level that would justify a growth-retail multiple.
On its own history, WRBY's valuation has compressed dramatically from its post-IPO peak, when the PS ratio reached 39.42x in Q4 2021 and 25.18x in Q1 2022, and the current 3.07x PS is near the low end of its historical band, which ranged roughly from 7x to 39x. The historical PE ratio has swung wildly from negative territory during loss-making quarters to 189.6x in Q2 2026, illustrating how unstable earnings-based valuation is for this name, while the price-to-book ratio of 7.27x compares with a historical range of roughly 4.2x to 18.3x. The compression from peak multiples suggests the market has already de-rated the stock substantially, but the current multiple still embeds optimistic assumptions about margin expansion, meaning the risk is skewed toward further multiple compression if growth or profitability disappoints.
PE
1626.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 151x~190x
vs. Industry Avg
29.4x
Industry PE ~29.4x*
EV/EBITDA
49.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on how little cushion exists beneath the profitability inflection. Trailing operating margin is -0.61% and net margin 0.19%, so a single quarter of gross margin slippage from the current 57.94% back toward the 52.97% level of Q2 2025 would erase GAAP profit entirely. Revenue is concentrated in eyewear products at $191.76 million of $235.51 million, meaning the 9.81% YoY growth rate in the core glasses business is the swing factor for the whole model, and Q4 2025's sequential revenue decline to $211.97 million from $221.68 million shows how seasonal softness can hit the top line. Free cash flow of $21.75 million TTM is modest against $22.86 million of quarterly capex, operating cash flow of $29.62 million covers capex only about 1.3x, and stock-based compensation of $9.90 million means reported earnings overstate economic profit.
Market and competitive risks are dominated by valuation compression. At 42.42x forward PE, 49.13x EV/EBITDA, 7.27x price-to-book, and 24.13x price-to-cash-flow, WRBY trades at a premium to brick-and-mortar optical and apparel retailers that typically command 1x-2x sales, and its 3.07x PS is only defensible if double-digit growth and margin expansion continue. A beta of 1.952 means the stock is nearly twice as sensitive to market moves as the S&P 500, so a risk-off rotation in consumer discretionary would hit WRBY disproportionately, and the 6-month relative strength of -11.11% versus SPY already shows that rotation underway. Competitive pressure from legacy optical chains, online contact lens sellers, and discount eyewear entrants threatens the price-disruption thesis, while any softening in discretionary consumer spending would pressure both store productivity and the pace of new openings.
The worst-case scenario is a growth-and-margin double miss: revenue growth decelerates below 5%, gross margin slips back toward the low-50s as promotional intensity rises, and the forward EPS estimate of $1.38 is cut, forcing the market to re-rate the stock from 42x toward a mid-20s multiple on lower earnings. That combination would plausibly take the stock back to the $21.29 recent low, roughly -18% from $26.08, and in a more severe de-rating toward the $14.96 52-week low the loss would be about -43%. The -39.22% historical max drawdown is a realistic guide to how far this name can fall in an adverse tape, and the $25.00 analyst low target sitting essentially at current price shows even the skeptics are not pricing a collapse — but with a beta near 2 and a 5.88-day short ratio, the path down would be fast and amplified.
FAQ
The most severe risk is margin fragility: trailing operating margin is -0.61% and net margin 0.19%, so a gross margin retreat from 57.94% back toward the 52.97% level of Q2 2025 would wipe out GAAP profit and invalidate the $1.38 forward EPS estimate underpinning the 42.42x multiple. Second is valuation compression: at 49.13x EV/EBITDA and 24.13x price-to-cash-flow, WRBY trades at a premium to retail peers, and a re-rating toward a mid-20s forward multiple would take the stock toward the $21.29 recent low, about -18%. Third is growth deceleration and concentration: revenue grew just 9.81% YoY, Q4 2025 revenue fell sequentially to $211.97 million from $221.68 million, and eyewear products are $191.76 million of $235.51 million in revenue, so the core glasses business is the single swing factor. Fourth is macro and volatility: a beta of 1.952 makes the stock nearly twice as sensitive as the S&P 500, the 6-month relative strength versus SPY is already -11.11%, and the -39.22% max drawdown shows how violent a risk-off episode can be, amplified by a 5.88-day short ratio.
The base case carries 50% probability with a $28.00-$31.00 range, assuming revenue growth of roughly 9%-11%, gross margin sustained near 57.94%, and forward EPS of about $1.38 delivered, keeping the stock range-bound between the $25.00 low target and the $31.00 average. The bull case at 25% probability targets $33.00-$35.00, requiring revenue growth back above 12%, gross margin at or above 58%, operating margin expanding past 3%, and analyst upgrades lifting the average target toward the $35.00 high. The bear case at 25% probability targets $21.00-$25.00, driven by growth below 5%, gross margin slipping toward the low-50s, and a forward EPS cut below $1.20 forcing a re-rating from 42x toward a mid-20s multiple. The base case is most likely because it requires only continuation of the current trajectory rather than acceleration, and the key assumption is that gross margin holds above 57% while the $1.38 EPS estimate survives intact.
The answer depends on the metric. On trailing earnings the 1,626x PE is meaningless because trailing EPS is just $0.0006, so the forward PE of 42.42x is the operative number, and it implies the market is paying in advance for EPS to inflect to the $1.38 consensus estimate. On sales, the 3.07x PS and 2.84x EV/sales are a premium to brick-and-mortar optical and apparel retailers that typically trade at 1x-2x sales, though WRBY's 53.97% gross margin is well above the low-30s to low-40s typical of mass retail. Against its own history the stock looks cheap: PS peaked at 39.42x in Q4 2021 and 25.18x in Q1 2022, so 3.07x sits near the bottom of a historical 7x-to-39x band, and price-to-book of 7.27x compares with a historical range of roughly 4.2x to 18.3x. The market is therefore pricing a maturing, margin-driven retailer rather than a hyper-growth story — fair value with an upward tilt if execution holds, but expensive relative to peers if growth stays below 10%.
The risk/reward is balanced rather than compelling at $26.08. Upside to the $31.00 average analyst target is +18.9%, and the $35.00 high target implies roughly +34%, backed by a 10 Buy / 3 Hold / 0 Sell consensus and a recommendation mean of 1.62. Against that, the stock trades at 42.42x forward PE and 49.13x EV/EBITDA on a business with a 0.19% trailing net margin, and the $25.00 low target sits essentially at the current price, capping the perceived downside in analyst eyes. The biggest downside risk is a gross margin slip toward the 52.97% level of Q2 2025, which would erase GAAP profit and force a re-rating toward the $21.29 recent low, roughly -18%. It is a reasonable buy for growth-oriented investors with a multi-year horizon who can tolerate a beta of 1.952 and want exposure to a credible margin inflection, but it is not a compelling entry for conservative or short-horizon investors until revenue growth reaccelerates above 12% or the stock breaks decisively above $31.00.
WRBY is better suited to a long-term holding period of at least 18-24 months than to short-term trading. The thesis depends on a multi-quarter margin and store-maturation story — gross margin expanding roughly 500bps YoY to 57.94% and operating income swinging to $3.17 million from a $4.53 million loss — which needs several prints to prove durable, and the 0% dividend yield means all return must come from price appreciation. Short-term trading is treacherous: beta of 1.952, a -39.22% max drawdown, a 5.88-day short ratio, and a +22.50% single-day spike from $21.29 to $26.08 on 11.26 million shares show how violently the stock can move in either direction. Earnings visibility is improving but still thin, with trailing net margin of 0.19% and ROE of 0.45%, so quarterly results can swing the narrative sharply. A concrete approach is a staged entry with a minimum 18-month horizon, adding on confirmation of gross margin above 57% and revenue growth above 12%, and reassessing if the stock closes below $21.29.